Immunome Inc. Files 2024 10-K, Details Capital Activities
Ticker: IMNM · Form: 10-K · Filed: Mar 19, 2025 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 10-K |
| Filed Date | Mar 19, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, capital-raising, agreements
TL;DR
Immunome's 2024 10-K is in! Lots of capital raises and deals with Zentalis & Ayala detailed.
AI Summary
Immunome Inc. filed its 2024 10-K on March 19, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company's fiscal year-end is December 31. Key financial activities include various capital-raising events such as public offerings, open market sales, and specific agreements like the License Agreement with Zentalis Pharmaceuticals Inc. and purchase agreements with Zentalis and Ayala.
Why It Matters
This filing provides investors with a comprehensive overview of Immunome's financial health and strategic transactions for the past fiscal year, crucial for understanding its operational status and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Immunome faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- $644,608,29 — Accrued Liabilities and Other Liabilities (Represents a significant liability category for the company as of the fiscal year end.)
- $43,251,778 — Accrued Liabilities and Other Liabilities (Prior Year) (Shows a decrease in accrued liabilities compared to the previous year.)
Key Players & Entities
- Immunome Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-19 (date) — Filing date
- Zentalis Pharmaceuticals Inc. (company) — Party to license and purchase agreements
- Ayala (company) — Party to a purchase agreement
FAQ
What was the total amount of Additional Paid-In Capital generated from the Public Offering Member in 2024?
The filing indicates that Additional Paid-In Capital was recognized under the PublicOfferingMember for the period 2024-01-01 to 2024-12-31, but a specific dollar amount is not provided in this excerpt.
What is the nature of the 'ZentalisPurchaseAgreementMember' and its impact on Additional Paid-In Capital?
The filing shows that the 'ZentalisPurchaseAgreementMember' contributed to 'AdditionalPaidInCapitalMember' during the 2024 fiscal year, indicating a capital infusion through this agreement.
How much Additional Paid-In Capital was recognized from the 'LicenseAgreementWithZentalisPharmaceuticalsInc.Member' in 2024?
The filing lists 'LicenseAgreementWithZentalisPharmaceuticalsInc.Member' as contributing to 'AdditionalPaidInCapitalMember' for the period 2024-01-01 to 2024-12-31, but the specific amount is not detailed in this section.
What was the fiscal year end for Immunome Inc. in this filing?
The fiscal year end for Immunome Inc. in this 10-K filing is December 31, 2024.
When was this 10-K filing submitted to the SEC?
This 10-K filing was submitted to the SEC on March 19, 2025.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 19, 2025 regarding Immunome Inc. (IMNM).